In this clinicopathological study that we conducted to confirm the in vitro result and determine the prognostic role of lipocalin-2 in prostate cancer patients, statistical analysis failed to show significant association between the levels of lipocalin-2 expression and the effectiveness of docetaxel although patients with high lipocalin-2 expression were more resistant to docetaxel (p=0.09). The gene discussed is LCN2; the disease is Familial prostate cancer.